In the last trading session, 1.29 million shares of the Replimune Group Inc (NASDAQ:REPL) were traded, and its beta was 0.69. Most recently the company’s share price was $9.34, and it changed around -$0.31 or -3.21% from the last close, which brings the market valuation of the company to $719.99M. REPL currently trades at a discount to its 52-week high of $17.00, offering almost -82.01% off that amount. The share price’s 52-week low was $6.44, which indicates that the current value has risen by an impressive 31.05% since then. We note from Replimune Group Inc’s average daily trading volume that its 10-day average is 1.36 million shares, with the 3-month average coming to 1.25 million.
Replimune Group Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.11. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended REPL as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Replimune Group Inc is expected to report earnings per share of -0.85 for the current quarter.
Replimune Group Inc (NASDAQ:REPL) trade information
Instantly REPL has showed a red trend with a performance of -3.21% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 9.90 on recent trading dayincreased the stock’s daily price by 5.66%. The company’s shares are currently up 15.45% year-to-date, but still up 0.54% over the last five days. On the other hand, Replimune Group Inc (NASDAQ:REPL) is -4.21% down in the 30-day period. We can see from the shorts that 9.32 million shares have been sold at a short interest cover period of 6.54 day(s).
The consensus price target as assigned by Wall Street analysts is $27, which translates to bulls needing to increase their stock price by 65.41% from its current value. Analyst projections state that REPL is forecast to be at a low of $27 and a high of $27.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 1.32M in revenue for the current quarter. 6 analysts expect Replimune Group Inc to make 6.63M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -14.85%. Replimune Group Inc earnings are expected to increase by 9.79% in 2025, but the outlook is positive 35.14% per year for the next five years.
REPL Dividends
Replimune Group Inc’s next quarterly earnings report is expected to be released on 2025-May-22.
Replimune Group Inc (NASDAQ:REPL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.51% of Replimune Group Inc shares, and 107.52% of them are in the hands of institutional investors. The stock currently has a share float of 112.60%. Replimune Group Inc stock is held by 228.0 institutions, with BAKER BROS. ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 14.5193% of the shares, which is about 10.05 million shares worth $90.41 million.
PRICE T ROWE ASSOCIATES INC /MD/, with 13.3496% or 9.24 million shares worth $83.13 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
T. Rowe Price New Horizons Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 4.67 shares worth $43.58 million, making up 6.05% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 1.99 shares worth around $18.57 million, which represents about 2.58% of the total shares outstanding.
